top of page

News

May 6, 2024


Azome Therapeutics, an early-stage drug development company, announced today that the company will present at the upcoming BioNJ Biopartnering Conference on May 14, 2024, in Jersey City, NJ. 


CEO Elliott Gruskin will highlight the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform and its lead drug candidate, AZM-152.  This novel antagonist platform, which blocks inflammasome activation, has demonstrated excellent potential for advancing the treatment of severe inflammatory diseases, including several with significant unmet needs.


Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, acute respiratory distress syndrome, bronchopulmonary dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key upstream priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade.

March 29, 2024


Azome Therapeutics, an early-stage drug development company, announced today that the company will present at the upcoming MedInvest Biotech & Pharma Investor Conference from April 3-4, 2024 in New York, NY.


One of more than 40 companies presenting at this year’s conference, Azome Therapeutics will highlight the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform and its lead drug candidate, AZM-152.  This novel antagonist platform, which blocks inflammasome activation, has demonstrated excellent potential for advancing the treatment of severe inflammatory diseases, including several that have significant unmet needs.


Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, acute respiratory distress syndrome, bronchopulmonary dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key upstream priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade.

January 18, 2024


Azome Therapeutics, an early-stage drug discovery company, announced today that the company has been selected to present at the upcoming 2024 Florida Venture Capital Conference from January 31 - February 1, 2024, in Miami, FL.  


One of 60 presenting companies, Azome Therapeutics, will highlight the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform and its lead drug candidate, AZM-152.  This novel antagonist platform, which blocks inflammasome activation, has demonstrated excellent potential for advancing the treatment of severe inflammatory diseases, including several that have significant unmet needs.


Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, acute respiratory distress syndrome, bronchopulmonary dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key upstream priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade.

bottom of page